Features | VJHemOnc

Highlights from the EBMT-EHA CAR T-cell 2022 Meeting

VJHemOnc is excited to bring you the latest research updates in CAR-T therapy from the EBMT-EHA 4th European CAR T-cell…

VJSocial Media Masterclass

Learn how to use Twitter alongside your clinical practice from leading hematology experts. Independent medical support by Janssen Pharmaceuticals

Brexucabtagene autoleucel receives FDA approval for R/R B-ALL

On October 1, 2021, the US Food and Drug Administration (FDA) approved the use of brexucabtagene autoleucel, an autologous CD19-directed…

IMW 2021: Heinz Ludwig and Hermann Einsele discuss meeting highlights

VJHemOnc is excited to bring insights from Maria Victoria-Mateos and Irene Ghobrial, as discussed at the 18th International Myeloma Workshop…

IMW 2021: myeloma updates with Maria-Victoria Mateos and Irene Ghobrial

VJHemOnc is excited to bring insights from Maria Victoria-Mateos and Irene Ghobrial, as discussed at the 18th International Myeloma Workshop…

Key trial updates from IMW 2021

VJHemOnc is excited to bring you the latest updates from 18th International Myeloma Workshop (IMW) 2021, which brought together leading…

Highlights from the Texas MPN Workshop 2021

VJHemOnc is excited to bring you the latest updates from The Texas MPN Workshop: Second Annual Workshop and Meeting, which brought…

BTK inhibitors for B-cell malignancies: managing and improving class-driven adverse events

Bruton’s tyrosine kinase (BTK) inhibitors fulfill an increasingly important role in the treatment of patients with B-cell malignancies including chronic…